Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Conference...
May 19 2021 - 5:00PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule single-agent and combination therapy
candidates for the treatment of non-alcoholic steatohepatitis
(NASH) and other chronic liver diseases, today announced that
management will be presenting at the UBS Global Healthcare Virtual
Conference on Monday, May 24 at 12:00 p.m. ET, and participating in
the J.P. Morgan Biotech 2021 CEO Conference Call Series on Tuesday,
May 25 at 1:00 p.m. ET.
A live audio webcast of the events will be available on the
investors page of the Terns Pharmaceuticals website at
http://ir.ternspharma.com. A replay of the webcasts will be
archived on Terns’ website for 30 days following the presentation.
J.P. Morgan Biotech 2021 CEO Conference Call Series webcasts
require registration.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule single-agent and
combination therapy candidates for the treatment of non-alcoholic
steatohepatitis, or NASH, and other chronic liver diseases. Terns’
programs are based on clinically validated and complementary
mechanisms of action to address the multiple hepatic disease
processes of NASH in order to drive meaningful clinical benefits
for patients. For more information, please visit
www.ternspharma.com.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
Media media@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2023 to Apr 2024